5219-15-8

Basic information

• Product Name: 6-bromo-4-phenyl-3-[(2E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]quinolin-2(1H)-one
• CAS NO: 5219-15-8
• Molecular Formula: C₁₂H₁₃FO₃
• Molecular Weight: 520.3713
• Mol File: 5219-15-8.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 694.2°C at 760 mmHg
• Flash Point: 373.7°C
• Density: 1.404g/cm³
• Vapor Pressure: 4.02E-19mmHg at 25°C
• Refractive Index: 1.641
• CAS DataBase Reference: 6-bromo-4-phenyl-3-[(2E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]quinolin-2(1H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 6-bromo-4-phenyl-3-[(2E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]quinolin-2(1H)-one(5219-15-8)
• EPA Substance Registry System: 6-bromo-4-phenyl-3-[(2E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]quinolin-2(1H)-one(5219-15-8)

Safety Data

• Hazardous Substances Data: 5219-15-8(Hazardous Substances Data)

Upstream product

• 141-97-9 ethyl acetoacetate 
• 460-00-4 1-Bromo-4-fluorobenzene 
• 108-24-7 acetic anhydride 
• 587-88-2 ethyl 2-(4-fluorophenyl)acetate 
• 141-78-6 ethyl acetate 

Downstream Products

• 1068515-21-8 4-(4-fluorophenyl)-3-methyl-1-(pyridin-2-yl)-1H-pyrazol-5-ol 

Relevant articles and documents

IMIDAZO [1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS

The invention provides substituted imidazo[1,5-a]pyrimidinyl carboxamide and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted imidazo[1,5-a]pyrimidinyl carboxamide compounds described herein include substituted 2-heterocyclyl-4-alkyl-imidazo[1,5-a]pyrirnidine-8-carboxamide compounds and variants thereof.

Synthesis and biological evaluation of substituted pyrazoles as blockers of divalent metal transporter 1 (DMT1)

Three distinct series of substituted pyrazole blockers of divalent metal transporter 1 (DMT1) were elaborated from the high-throughput screening pyrazolone hit 1. Preliminary hit-to-lead efforts revealed a preference for electron-withdrawing substituents in the 4-amido-5-hydroxypyrazole series 6a-l. In turn, this preference was more pronounced in a series of 4-aryl-5- hydroxypyrazoles 8a-j. The representative analogs 6f and 12f were found to be efficacious in a rodent model of acute iron hyperabsorption. These three series represent promising starting points for lead optimization efforts aimed at the discovery of DMT1 blockers as iron overload therapeutics.